Hematologic Cancers

Some Discrepancies Seen Between Real-Life and Guideline-Recommended Care of Chronic Myeloid Leukemia

By

Megan Garlapow, PhD

Publish Date August 20, 2019

An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.

10-Year OS After Bone Marrow Transplantation for CML Similar With/Without Prior TKI Therapy

By

Susan Moench, PhD, PA-C

Publish Date August 16, 2019

Researchers sought to determine whether late mortality rates are affected by exposure to a BCR-ABL TKI prior to BMT in patients with CML who survive at least 2 years posttransplantation.

Hematological Malignancy Risk Up for First-Degree Relatives

Publish Date August 15, 2019

Increased familial relative risks for the same tumor type for most hematological malignancies.

HLA-B27 Positivity Did Not Influence CLL, SLL Outcomes

By

Leah Lawrence

Publish Date August 14, 2019

Further studies needed to look at relevance outside of the transplant-eligible population.

Ruxolitinib Safe, Effective for Hydroxyurea Intolerant/Resistant Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date August 14, 2019

An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.